Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

186.06 +5.69 (+3.15%)
Official Closing Price Updated: 7:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
78 79 Next >
Is AbbVie Stock Too Pricey to Touch Right Now?
Other pharmaceutical companies are trading for far lower multiples. 
Via The Motley Fool
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Investors wonder if the healthcare giant can keep raising its payout now that it no longer sells the consumer health brands that made it famous. 
Via The Motley Fool
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF). 
Via Benzinga
Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
Some things are different about J&J. But other things remain the same as they've been for a long time. 
Via The Motley Fool
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
Looking Into AbbVie's Recent Short Interest
Via Benzinga
Looking At AbbVie's Recent Unusual Options Activity
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
These three top-notch stocks would make great additions to any dividend portfolio. 
Via The Motley Fool
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
3 Dividend Growth Stocks You Can Buy and Hold Forever
Investors can sit back and let the dividends flow in with these great stocks. 
Via The Motley Fool
7 Dividend Kings to Buy for Royal Returns
These dividend kings earn consistent income from steadily growing payments. Buy these stocks that have risen for 50 years or more. 
Via InvestorPlace
Should You Load Up On This 1 Dividend Stock?
It's not that hard a call. 
Via The Motley Fool
Check Out What Whales Are Doing With ABBV
Via Benzinga
ABBV Stock: Buy for the Yield, Hold for This Other Reason
"Safe harbor" status and a high, growing dividend yield isn't the only thing that's appealing with ABBV stock. 
Via InvestorPlace
Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks.
The successful hedge fund manager hasn't had a perfect record with his economic predictions in recent years. 
Via The Motley Fool
Topics Economy
Exposures Economy
3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years
These stocks are potential bargain buys for investors right now, just waiting to get scooped up. 
Via The Motley Fool
The 3 Best Defensive Stocks for Nervous Investors
The best defensive stocks are especially worth considering at the moment as volatility spikes and confidence wavers. 
Via InvestorPlace
AbbVie Stock Moves Higher With Rising Relative Strength
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue? 
Via Investor's Business Daily
3 Dividend Kings Every Investor Should Own to Survive a Market Crash
Dividend stocks that raise their payout beat all other kinds of stocks, making Dividend Kings the best stocks to buy in a downturn. 
Via InvestorPlace
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
2 Magnificent Dividend Stocks to Buy Hand Over Fist in October
These two healthcare stocks are reliable passive income vehicles. 
Via The Motley Fool
Retirement Royalty: 3 Dividend Aristocrats for a Steady Income Stream
These dividend aristocrats are some of the best options for long-term investors looking to boost their portfolio return. 
Via InvestorPlace
Topics Retirement
Exposures Pension
7 Top Healthcare Stocks That Pay Dividends
With uncertainty being the dominant theme of the moment, investors should consider healthcare stocks that pay dividends. 
Via InvestorPlace
3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 Years
These are relatively safe income investments that you can hold on to for the long haul. 
Via The Motley Fool
3 Top Stocks to Buy in October and Hold Forever
Check out these three blue chip buys playing crucial roles in America's $6 trillion healthcare opportunity. 
Via The Motley Fool
These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now
These defensive index funds can help investors hedge against a possible recession. 
Via The Motley Fool
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.